UY24268A1 - Composiciones estables de vacunas para la administración parenteral, método para su utilización - Google Patents

Composiciones estables de vacunas para la administración parenteral, método para su utilización

Info

Publication number
UY24268A1
UY24268A1 UY24268A UY24268A UY24268A1 UY 24268 A1 UY24268 A1 UY 24268A1 UY 24268 A UY24268 A UY 24268A UY 24268 A UY24268 A UY 24268A UY 24268 A1 UY24268 A1 UY 24268A1
Authority
UY
Uruguay
Prior art keywords
compound
vaccine compositions
mixture
stable vaccine
parenteral administration
Prior art date
Application number
UY24268A
Other languages
English (en)
Inventor
Christopher Leigh Schwartzkoff
Ramune Marija Cobb
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21692234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY24268(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Priority to UY24281A priority Critical patent/UY24281A1/es
Publication of UY24268A1 publication Critical patent/UY24268A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/842—Clostridium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/843—Corynebacterium

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a ciertas composiciones estables para vacunas que comprenden un compuesto que es lactona macrocíclica; un compuesto que es milbemicina; un compuesto que es avermectina o mezcla de los mismos; por lo menos un antígeno; un agente dispersante; un agente adyuvante; un compuesto orgánico soluble en agua y una mezcla salina o agua o mezcla de las mismas. Asimismo, se reivindica un procedimiento de preparación de las antedichas composiciones, útiles para prevenir o controlar la helmintiasis, infecciones por ácaros y artrópodos endo y ectoparásitos, enfermedades bacterianas y virales en animales de sangre caliente.
UY24268A 1995-06-30 1996-06-27 Composiciones estables de vacunas para la administración parenteral, método para su utilización UY24268A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UY24281A UY24281A1 (es) 1995-06-30 1996-07-15 Procedimiento para preparar composiciones estables de vacunas para la administracion parenteral

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60595P 1995-06-30 1995-06-30

Publications (1)

Publication Number Publication Date
UY24268A1 true UY24268A1 (es) 2001-10-25

Family

ID=21692234

Family Applications (2)

Application Number Title Priority Date Filing Date
UY24268A UY24268A1 (es) 1995-06-30 1996-06-27 Composiciones estables de vacunas para la administración parenteral, método para su utilización
UY24281A UY24281A1 (es) 1995-06-30 1996-07-15 Procedimiento para preparar composiciones estables de vacunas para la administracion parenteral

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY24281A UY24281A1 (es) 1995-06-30 1996-07-15 Procedimiento para preparar composiciones estables de vacunas para la administracion parenteral

Country Status (15)

Country Link
US (2) US5989566A (es)
EP (1) EP0750907B1 (es)
AR (1) AR003445A1 (es)
AT (1) ATE214603T1 (es)
AU (1) AU708464B2 (es)
BR (1) BR9602939A (es)
DE (1) DE69619894T2 (es)
DK (1) DK0750907T3 (es)
ES (1) ES2174027T3 (es)
NZ (1) NZ286896A (es)
PT (1) PT750907E (es)
RU (1) RU2213574C2 (es)
SI (1) SI0750907T1 (es)
UY (2) UY24268A1 (es)
ZA (1) ZA965539B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7349596A (en) * 1995-05-17 1996-12-11 International Centre of Insect Physiology and Ecology, The Novel method of enhancing efficiency of anti-arthropod agents against blood-feeding ectoparasites
WO1997046204A2 (en) * 1996-06-05 1997-12-11 Ashmont Holdings Limited Injectable compositions
US6790445B1 (en) 1997-02-06 2004-09-14 Merck & Co., Inc. Preservatives for vaccines
CA2278684C (en) * 1997-02-06 2007-04-10 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
UY25089A1 (es) * 1997-07-10 2000-08-21 Hoechst Roussel Vet Gmbh Vacunas no acuosas
US6524592B2 (en) * 1997-10-17 2003-02-25 American Home Products Corporation Veterinary vaccines
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
GB9801109D0 (en) * 1998-01-20 1998-03-18 Pfizer Cyclodextrin compositions
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006518193A (ja) * 2003-01-16 2006-08-10 ユニバーシティ オブ バージニア パテント ファウンデーション 精子特異的リゾチーム様タンパク質
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
CH697021A5 (de) * 2003-06-26 2008-03-31 Merck Eprova Ag Stabile pharmazeutische Zusammensetzungen von 5, 10-Methylentetrahydrofolat.
NZ529177A (en) * 2003-10-24 2005-12-23 Agres Ltd Administration process for a delivery device that releases the active agent over several days
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
KR20120042865A (ko) * 2006-03-30 2012-05-03 엠브렉스, 인코포레이티드 가금류의 예방접종 방법 및 조성물
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20090053335A1 (en) * 2007-04-13 2009-02-26 Chih-Hui Lin Herbal compositions for the inhibition of human immunodeficiency virus (hiv)
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
MX2009012924A (es) * 2007-06-08 2010-03-25 Australian Poultry Crc Pty Ltd Toxina clostridial netb.
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
RU2381807C1 (ru) * 2008-07-18 2010-02-20 Алексей Глебович Одинец Противовирусное средство
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8313752B2 (en) * 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same
MX2012004133A (es) 2009-10-07 2012-05-08 Wyeth Llc Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas.
CA2839507A1 (en) * 2011-06-24 2012-12-27 Epitogenesis Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
US10059710B2 (en) 2016-02-17 2018-08-28 Merck & Cie Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171125A (en) * 1966-06-08 1969-11-19 Glaxo Lab Ltd Improvements in or relating to Injectable Preparations
US3885011A (en) * 1971-12-29 1975-05-20 Janssen Pharmaceutica Nv Vaccine adjuvants
SU627612A1 (ru) * 1977-09-30 1980-02-05 Zemlyakova V P Препарат земл ковой в.п. против клюстридиозов животных и птиц
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS62294623A (ja) * 1986-02-26 1987-12-22 Nisshin Flour Milling Co Ltd サルモネラ感染症予防剤
GB8906234D0 (en) * 1989-03-17 1989-05-04 Albright & Wilson Agrochemical suspensions
US4988824A (en) * 1989-09-11 1991-01-29 Maulding Donald R Process for the preparation of 23-(C1-C6 alkyloxime)-LL-F28249 compounds
US5262400A (en) * 1991-06-20 1993-11-16 Merck & Co., Inc. 4α-substituted avermectin derivatives
US5284877A (en) * 1992-06-12 1994-02-08 Merck & Co., Inc. Alkyl and alkenyl macrolides having immunosuppressive activity
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen

Also Published As

Publication number Publication date
US20020102266A1 (en) 2002-08-01
EP0750907B1 (en) 2002-03-20
DE69619894T2 (de) 2002-11-14
US6746677B2 (en) 2004-06-08
DE69619894D1 (de) 2002-04-25
SI0750907T1 (en) 2002-08-31
ES2174027T3 (es) 2002-11-01
PT750907E (pt) 2002-08-30
UY24281A1 (es) 1996-12-26
AR003445A1 (es) 1998-08-05
AU708464B2 (en) 1999-08-05
US5989566A (en) 1999-11-23
BR9602939A (pt) 1998-04-22
RU2213574C2 (ru) 2003-10-10
EP0750907A3 (en) 1998-05-06
EP0750907A2 (en) 1997-01-02
NZ286896A (en) 1998-05-27
DK0750907T3 (da) 2002-07-08
ATE214603T1 (de) 2002-04-15
AU5625696A (en) 1997-01-09
ZA965539B (en) 1998-03-30

Similar Documents

Publication Publication Date Title
UY24268A1 (es) Composiciones estables de vacunas para la administración parenteral, método para su utilización
AR003433A1 (es) Agente ectoparasiticida, procedimiento para la produccion de dicho agente uso de un compuesto contra insectos parasitos y garrapatas monofagas y para laproduccion de dicho agente.
DE69725745D1 (de) Injizierbare zusammensetzungen
SE8802985D0 (sv) Kemiska foreningar och forfarande for deras framstellning
NO2011026I2 (no) Eribulin eller et farmasøytisk akseptabelt salt derav
DE3575927D1 (de) Purinderivate, verfahren zu ihrer herstellung und pharmazeutische zubereitung.
ES2723779T3 (es) Formulación para el control de piojos y garrapatas en el ganado
ES2070131T3 (es) Sistemas farmaco-lipido de baja toxicidad.
DK0810823T3 (da) Sammensætning til bekæmpelse af parasitter
ATE173738T1 (de) Alkylthioalkylavermectine sind aktive antiparasitäre wirkstoffe
ES2086022T3 (es) Composiciones estables para administracion parenteral y su uso.
KR950005306A (ko) 매크롤라이드 및 그의 용도
ATE207492T1 (de) Difluoroavermectin-derivate
EP1197207A3 (en) Stable compositions for parenteral administration
ES2152947T3 (es) Una cepa de streptomyces avermitilis y compuestos de avermectina glicosilados.
GT199100050A (es) Procedimientos para la produccion de fungicidas.

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20160627